Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Specifically activated memory T cell subsets from cancer patients recognize and reject xenotransplanted autologous tumors
Philipp Beckhove, … , Volker Schirrmacher, Viktor Umansky
Philipp Beckhove, … , Volker Schirrmacher, Viktor Umansky
Published July 1, 2004
Citation Information: J Clin Invest. 2004;114(1):67-76. https://doi.org/10.1172/JCI20278.
View: Text | PDF
Article Oncology

Specifically activated memory T cell subsets from cancer patients recognize and reject xenotransplanted autologous tumors

  • Text
  • PDF
Abstract

Bone marrow of breast cancer patients was found to contain CD8+ T cells specific for peptides derived from breast cancer–associated proteins MUC1 and Her-2/neu. Most of these cells had a central or effector memory phenotype (CD45RA–CD62L+ or CD45RA–CD62L–, respectively). To test their in vivo function, we separated bone marrow–derived CD45RA+ naive or CD45RA–CD45RO+ memory T cells, stimulated them with autologous dendritic cells pulsed with tumor lysate, and transferred them into NOD/SCID mice bearing autologous breast tumors and normal skin transplants. CD45RA– memory but not CD45RA+ naive T cells infiltrated autologous tumor but not skin tissues after the transfer. These tumor-infiltrating cells had a central or effector memory phenotype and produced perforin. Many of them expressed the P-selectin glycoprotein ligand 1 and were found around P-selectin+ tumor endothelium. Tumor infiltration included cluster formation in tumor tissue by memory T cells with cotransferred dendritic cells. It was associated with the induction of tumor cell apoptosis and significant tumor reduction. We thus demonstrate selective homing of memory T cells to human tumors and suggest that tumor rejection is based on the recognition of tumor-associated antigens on tumor cells and dendritic cells by autologous specifically activated central and effector memory T cells.

Authors

Philipp Beckhove, Markus Feuerer, Mathias Dolenc, Florian Schuetz, Carmen Choi, Nora Sommerfeldt, Jochen Schwendemann, Katrin Ehlert, Peter Altevogt, Gunther Bastert, Volker Schirrmacher, Viktor Umansky

×

Figure 1

Options: View larger image (or click on image) Download as PowerPoint
TA specificity and function of BM memory T cells from breast cancer pati...
TA specificity and function of BM memory T cells from breast cancer patients. (A) T cells were stained with tetramers containing HLA-A2 and the MUC1 peptide LLLLTVLTV or the irrelevant HIV peptide SLYNTVATL. Representative data are shown. Blue, low density of cells; yellow, high density of cells. (B and C) Frequencies of MUC1- or Her-2/neu–specific CD8+ T cells from BM and PB of patients (P) and healthy donors (HD). Maximal levels of tetramer-binding CD8+ T cells from healthy donors are depicted by dotted lines. Frequencies of HIV-specific CD8+ T cells from BM and PB of nine breast cancer patients are shown. Maximum levels of nonspecific bindings are depicted by solid lines. (D) Accumulative data for MUC1- and Her-2/neu–binding CD8+ T cells expressing memory markers (seven and six patients, respectively). *P < 0.0001, memory versus naive cells; *P < 0.0001, EM versus CM cells. (E) Frequencies of Her-2/neu–specific BM T cells from patients or healthy donors, measured by IFN-γ ELISPOT after stimulation by DCs pulsed with the Her-2/neu peptide KIFGSLAFL. (F) MUC1-specific cytotoxicity of BM T cells. Patient (filled squares and filled triangles) or donor (open circles) cells were stimulated for 5 days with DCs pulsed with the MUC1 peptide LLLLTVLTV. HLA-A2+ T2 target cells were loaded with LLLLTVLTV (filled squares, open circles) or SLYNTVATL (filled triangles) peptides. X axis represents effector/target (E/T) ratios.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts